In recognition of Head and Neck Cancer Awareness Month, Oncofocus has released a concise and easy-to-read infographic that outlines the current approved therapies and noteworthy emerging therapies. Stay informed and help spread HNC awareness with this publicly accessible infographic.

Since March is Multiple Myeloma Awareness Month, we at Oncofocus have created an informative infographic highlighting the current treatment options and emerging therapies for Multiple Myeloma.

Biliary tract cancers, encompassing bile duct and gallbladder malignancies, originate from the bile duct epithelium. Cholangiocarcinoma, or bile duct cancer, affects approximately 8,000 individuals annually in the United States, while gallbladder cancer is even less common, with an incidence rate of about 2 per 100,000 people. These cancers are frequently diagnosed at advanced stages, leading to poor prognoses. In the US and EU, treatment options remain scarce, although recen

Focus: Multiple Myeloma Indication Multiple Myeloma is the second most common hematologic malignancy and is largely considered incurable. The promising results obtained with the bluebird bio’s idecabtagene vicleucel (bb2121) and Janssen - Legend Biotech’s JNJ-68284528 (LCAR-B38M) brought CAR-Ts at the forefront of the clinical research. B-cell Maturation Antigen (BCMA) is an antigen that has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting

Focus - Melanoma Indication Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer-related deaths globally. With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. With the approval of nivolumab and pembrolizumab (both are PD-1 targeting age

Focus - Small Cell Lung Cancer Indication SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of lung cancer cases globally and is also a major cause of cancer-related deaths. Chemotherapy has been the mainstay in SCLC management. While the response rate to chemotherapy is high, notably, almost all patients relapse after a few months (PFS is typically 4.0 - 5.5 months). Immunotherapy, which changed the treatment paradigm in Mela